Lonza Acquires Biotech Service Provider Algonomics

Lonza integrates Innovative Technology in its Protein Design Services offering

10-Nov-2009 - Belgium

Lonza strengthens its protein design technology offering for biopharmaceutical development by acquiring AlgoNomics NV. Algonomics is a contract research organisation providing integrated immunogenicity prediction services to support companies in the development of biotherapeutics. Effective 2 November 2009 Lonza has acquired all shares of Algonomics including the proprietary Epibase, Epibase IV and Tripole technology platforms as well as the existing services business. The purchase price was not disclosed.

“The acquisition of this business is in line with our goal to offer a compelling portfolio of services and technologies for the creation, optimization and development of advanced, best in class biopharmaceuticals”, said Janet White, Head of Lonza Development Services & Biologics R&D. “With the combined technologies of Lonza and Algonomics we can significantly strengthen our offering for our customers”.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances